Phase Genomics is an American biotechnology company based in Seattle, Washington. The company specializes in developing proximity ligation kits and Hi-C sequencing technology used to analyze chromosomes. They also offer scientific services and computational analyses.

Phase Genomics

Genome Startup Day

Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. They offer a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples as well as industry-leading genome and metagenome assembly and analysis software.  
Founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs, the company’s mission is to empower scientists with state-of-the-art genomic tools that will accelerate breakthrough discoveries. The company serves academic and commercial researchers in diverse fields and industries.

Bill & Melinda Gates Foundation

National Institute of Allergy and Infectious Diseases

National Institutes of Health

Washington Research Foundation

Congruent Ventures

Sahsen Ventures

Hemi Ventures

We are honored to receive the Metagenomics Innovation Of The Year Award for 2023 from BioTech Breakthrough! From worms to wastewater, our team has been taking in samples from around the globe to compile the world’s largest phage-host interactome to fuel research including combatting and tracking AMR, biodefense, and phage therapy. Read more here: https://hubs.la/Q028d2Hz0 

Discover the power of proximity ligation, unlock platinum #genomes, and talk with our experts at #PAG31! We’re excited to see everyone at this year’s International Plant and Animal Genome Meeting. Stop by booth 222 to learn how Proximo maximizes insights & drives genomic discovery. More here: https://hubs.la/Q02fSJw_0

From constructing the world’s largest phage-host atlas to progressing precision medicine, 2023 has been a year of great discoveries. Join us in reflecting on all the milestones in our latest blog. Thank you for being part of our story and happy new year from Phase Genomics! https://hubs.la/Q02dWVpz0

I will be traveling to #ash23 in San Diego and look forward to many exciting meetings. Please feel free to reach out, I would love to connect!

This Friday, join us at #ICME2023 for a presentation on how recent advancements in #metagenomics and #microbiology are being used to power global biodefense, track & prevent AMR, and accelerate phage-based therapeutic discoveries. Visit us at our table to learn more! 
AIChE - American Institute of Chemical Engineers

Metric
Company Name	Phase Genomics
Symbol
MSH ID	COM:PHASEGENOMICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	31
Website	phasegenomics.com
LinkedIn	phase-genomics-inc
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	95.53
28-Day Growth Score	22.80
90-Day Growth Score	23.51
365-Day Growth Score	40.31

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:PHASEGENOMICS

Phase Genomics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue